Background
==========

Successful hemostasis has always been fundamental in all surgical procedures. Ligature and diathermocoagulation are the main hemostatic methods; however, since 1909, with the use of fibrin \[[@b1-amjcaserep-19-812]\], numerous hemostatic agents (HA) have become available. In 1945, oxidized cellulose (OC) was introduced in surgery and it has become one of the major HAs because of its ease of use, favorable biocompatibility, and bactericidal properties \[[@b2-amjcaserep-19-812]--[@b4-amjcaserep-19-812]\]. Several OCs are available and classified in regenerated oxidized cellulose (ROC; e.g. Surgicel^®^ -- Johnson and Johnson, Somerville, NJ, USA) and non-regenerated oxidized cellulose (nROC; e.g., Oxycell^®^ -- Becton Dickinson, Franklin Lakes, NJ, USA). Although the manufacturers recommend the OC removal after its use, it is generally left *in situ* because of its high level of reabsorption that lasts up to 8 weeks. However, several cases of retained OC with severe complications have been reported in the literature. Here, we describe a complication that was associated with the use of Gelita-Cel^®^ Standard (ROC; Gelita Medical, Eberbach, Germany) and we review the literature to better define the purpose and limits of OC as a hemostatic agent.

Case Report
===========

A 51-year-old male patient presented in our emergency department with acute abdominal pain, nausea, and vomiting. Laboratory test results were normal with no evidence of inflammation markers (white blood cells: 8.03×10^3^/µl; neutrophils: 68.2%; C reactive protein: 3 mg/l). He had been admitted to our department for laparoscopic cholecystectomy for acute cholecystitis 25 months previously. The patient complained of moderate abdominal pain since his first operation; therefore, he had abdominal CT scan at 6 months, showing evidence of a circular mass (39×34 mm) with fluid content (density 35--45 HU). In addition, an abdominal US at 24 months showed a non-vascularized mass in the liver bed that was suspected to be a granuloma. The patient was admitted for an abdominal CT scan and the results confirmed a circular cystic mass with homogeneous fluid content, close to the surgical clips of the previous surgery, resembling a "neo-gallbladder" ([Figure 1](#f1-amjcaserep-19-812){ref-type="fig"}). Although the patient had no signs of inflammation or infection, a hepatic abscess was suspected based on imaging results and previous surgical history. To better define the patient's unclear clinical condition, we chose to perform a surgical drainage instead of a percutaneous (US- or CT-guided). Therefore, the patient underwent laparoscopic abdominal exploration, incision of the hepatic bed mass, and drainage of amorphous, brown, dense material ([Figure 2](#f2-amjcaserep-19-812){ref-type="fig"}). A drain was left in the liver bed and was removed on the 2^st^ postoperative day. Histological examination reported protein-based amorphous material with rare lymphocytes and macrophages. Culturing was negative for bacterial growth. After antibiotic prophylaxis with extended spectrum B-lactam, the patient was discharged without symptoms on the 4^th^ postoperative day. The primary surgical report was evaluated for evidence of use of Gelita-Cel^®^ Standard for hemostatic purposes. The 12-month follow-up was uneventful.

Discussion
==========

Bleeding can be a major intraoperative complication during surgical procedures. When conventional methods such as ligature and diathermocoagulation are ineffective for bleeding management, hemostatic agents (HA) can be used. In 1909, fibrin was described as an effective HA \[[@b1-amjcaserep-19-812]\] and since then numerous hemostatic devices have been used such as topical thrombin, porcine collagen, and OC \[[@b5-amjcaserep-19-812]\]. OC was first used for medical purposes in 1945 \[[@b2-amjcaserep-19-812],[@b3-amjcaserep-19-812]\], and since then it has been widely used in surgery, with several forms available. OC is easy to use and has good biocompatibility and bactericidal properties \[[@b4-amjcaserep-19-812]\]. OC is made of cellulose, which is a homopolysaccharide of glucopyranose polymerized through β-glucosidic bonds \[[@b6-amjcaserep-19-812],[@b7-amjcaserep-19-812]\]. Cellulose can be either regenerated to form organized fibers or non-regenerated with unorganized fibers prior to oxidation. When cellulose fibres are oxidized, conversion of hydroxyl groups to carboxylic acid groups occurs, yielding polyuronic acid \[[@b6-amjcaserep-19-812],[@b7-amjcaserep-19-812]\]. The low pH of the carboxylic acid groups is responsible for several actions: primary local hemostyptic action, secondary platelet activation to form a temporary platelet plug \[[@b6-amjcaserep-19-812],[@b7-amjcaserep-19-812]\], and hostile acidic environmental conditions for bacterial survival \[[@b8-amjcaserep-19-812]\]. Moreover, the knit structure and thickness of the gauge is responsible for bactericidal properties, with thinner loose-knit patterns being less effective than thicker tight-knit patterns against antibiotic-resistant microorganisms \[[@b9-amjcaserep-19-812]\].

Oxidized regenerated cellulose (ROC) is a re-absorbable material that can be intentionally left in the surgical field. *In vivo* studies on rats were performed to analyze the tissue reaction to locally implanted hemostatic agents \[[@b10-amjcaserep-19-812]\]. ROC absorption starts after 24--48 h; at day 7 the gauze is surrounded by inflammatory granulation tissue, and complete degradation occurs between 4--8 weeks \[[@b6-amjcaserep-19-812],[@b10-amjcaserep-19-812],[@b11-amjcaserep-19-812]\]. However, absorption is not always complete, with consequent gauze retention as first described by Vanderhoof et al. \[[@b12-amjcaserep-19-812]\]. Therefore, it is common for ROC to appear as a mass during the immediate postoperative period, mimicking a postoperative abscess \[[@b13-amjcaserep-19-812]\], tumor \[[@b14-amjcaserep-19-812]\], or hematoma \[[@b15-amjcaserep-19-812]\], posing a serious challenge in differential diagnosis \[[@b16-amjcaserep-19-812]\].

On CT scan, a retained OC may appear as a mixed- or low-attenuation mass containing a focal central collection of gas, located inside or near the operative site, with a faint enhancement at the mass periphery and absence of air-fluid levels \[[@b13-amjcaserep-19-812],[@b17-amjcaserep-19-812],[@b18-amjcaserep-19-812]\] ([Table 1](#t1-amjcaserep-19-812){ref-type="table"}). Over time, the central collection of air is completely replaced by soft tissue, leading to the formation of a foreign-body granuloma \[[@b13-amjcaserep-19-812]\].

MRI findings are nonspecific, but the presence of hypoin-tense stripes inside a cystic-like cavity on T2-weighted images is considered to be a characteristic sign of ROC-associated granuloma \[[@b19-amjcaserep-19-812]\].

PET/CT images may produce false-positive results in case of foreign body granuloma as a consequence of localized inflammation, mimicking malignant tissue glucose uptake \[[@b20-amjcaserep-19-812]--[@b22-amjcaserep-19-812]\].

Retained OC is frequently found in ultrasound imaging (US) as a complex mass or well-encapsulated hypo-isoechoic lesion with circumscribed margins and internal hyperechoic nodules at the surgical site \[[@b23-amjcaserep-19-812]\]. The presence of hyper-isoechoic nodules within a complex cystic mass can be explained as typical granulomatous foreign body reaction induced by the presence of ROC and was described by Giuliani et al. as "ileflottante" \[[@b23-amjcaserep-19-812],[@b24-amjcaserep-19-812]\]. Moreover, the use of color/power Doppler should be considered as part of the ultrasound procedure. A perilesional vascularization is probably indicative of compression exerted by OC on neighboring tissues or connected to the presence of granulation tissue around the surgical site \[[@b25-amjcaserep-19-812],[@b26-amjcaserep-19-812]\]. Nevertheless, imaging can be useful and clinical evaluation is fundamental in confirming diagnostic suspicion.

We reviewed the literature and retrieved a total of 28 papers comprising 38 cases of OC retention. The details of cases are shown in [Table 2](#t2-amjcaserep-19-812){ref-type="table"}. Surgical sites included: brain (6), cervical spine (1), thoracic spine (1), thorax (10), abdomen (12), and pelvis (8). Twenty-nine patients received Surgicel ®, 2 received Oxycel^®^, 1 received Surgiflo^®^ (Johnson and Johnson, Somerville, NJ, USA), and 6 received non-specified OC ([Table 2](#t2-amjcaserep-19-812){ref-type="table"}). Here, we report the first case of complications due to Gelita-Cel^®^ retention.

The preoperative diagnosis and surgical procedure are described in [Table 2](#t2-amjcaserep-19-812){ref-type="table"}. The times from primary surgery to detection of retained OC ranged between 2 hours and 630 days. Twelve cases were incidental and the others were symptomatic. Various symptoms were described, ranging from malaise and fever to paraplegia, cauda equina syndrome, and vision impairment. Diagnostic suspicion was tumor recurrence (6), abscess (7), cord compression (6), granuloma (4), extradural mass (3), heterogeneous mass (3), gas collection (2), kidney tumor (2), ovarian cancer (1), hematoma (1), abscess/hematoma (1), granuloma/neoplasm (1), and non-specified lesion (1). Gauze removal was performed in 27 cases. In 2 patients, removal of the gauze required a major procedure: 1 patient underwent nephrectomy and another had allograft extirpation that resulted in need for dialysis.

Despite the fundamental importance of OC as an essential hemostatic agent in surgery, some precautions are needed to avoid future complications. Although 38 cases, in addition to our reported case, are very few compared to all surgical procedures performed with OC use with no associated complication, complications may also be severe and associated with risky surgical procedures.

Our review of the literature found that 8 patients experienced paraplegia, which occurred between 2 hours and 2 days after thoracic surgery \[[@b27-amjcaserep-19-812]--[@b29-amjcaserep-19-812]\]; cord compression was suspected and urgent laminectomy was performed, revealing a mass of Surgicel^®^ in the extradural space. A surgical report showed the use of OC to control difficult bleeding from the posterior angle of the thoracotomy incision. The posterior end of the rib adjacent to the gaping thoracostomy is usually a bleeding site that is hard to manage. During thoracostomy closure, the rib approximation may produce a compressive force on the OC, forcing it to migrate into the adjacent foramen. The established negative pressure of the intravertebral subdural space can enhance this pressure gradient and cause OC herniation with consequent symptomatology \[[@b26-amjcaserep-19-812]\]. Product information warns against leaving OC *in situ* next to foramina after hemostasis due to swelling, which can result in nerve damage due to pressure in a bony confined area \[[@b30-amjcaserep-19-812]\]. However, there is no report regarding the potential of material migration. Five out of 6 patients presented with total motor and sensory deficit, with extension according to the cord compression site \[[@b27-amjcaserep-19-812]--[@b29-amjcaserep-19-812]\]: one had spastic monoplegia involving the right leg \[[@b28-amjcaserep-19-812]\], one patient has to use a cane to walk \[[@b27-amjcaserep-19-812]\], and one has walking impairment requiring leg braces and obligatory catheterization \[[@b27-amjcaserep-19-812]\].

In circumstances requiring extensive dissection in the costovertebral angle, precise technique is imperative. Uncontrolled or poorly controlled bleeding in an intervertebral foramen should be an indication for consultation of a neurological surgeon.

Dutton et al. \[[@b32-amjcaserep-19-812]\] reported a case of compressive optic neuropathy after OC migration from the anterior cranial fossa into the orbital apex through an orbital roof fracture. Banerjee et al. \[[@b33-amjcaserep-19-812]\] reported a case of cauda equina syndrome treated with OC removal and consequent severe impairment of quality of life. To avoid major complications, particular attention must be paid to hemostatic control in rigid inextensible anatomical structures such as the skull and spinal cord.

In 9 cases, tumor mass or neoplasm recurrence was suspected, with consequent resective treatment. Somani et al. \[[@b34-amjcaserep-19-812]\] reported a case of clinically/radiologically suspected renal cell carcinoma in a patient who previously underwent splenectomy for myelofibrosis, evidenced as an heterogenous kidney mass formation on abdominal CT scan with paraortic lymph-adenopathy. Nephrectomy was performed, but histology did not show a neoplasm and instead found a foreign-material granuloma. This is an important case of retained OC mimicking a neoplasm. Azmy et al. \[[@b35-amjcaserep-19-812]\] reported a case of OC removal in a patient suspected to have a recurrence of neuroblastoma.

Royds et al. \[[@b36-amjcaserep-19-812]\] documented the first case of local tissue reaction associated with Surgicel^®^ in head and neck surgery, with removal and resolution confirming its cause. Concha et al. \[[@b37-amjcaserep-19-812]\] reported a case of xanthogranulomatous pyelonephritis caused by OC retention in a renal allograft, with consequent extirpation of the allograft and return to dialysis in a 41-year-old patient. Arnold et al. \[[@b38-amjcaserep-19-812]\] documented an abscess mimicking a mass following cholecystectomy and liver biopsy.

Among all 38 cases described, plus our reported case, 11 patients were treated conservatively due to suspicion of an OC-retaining lesion after surgical history evaluation and multidisciplinary analysis by surgeons and radiologists. Although retained OC has been described by many authors \[[@b27-amjcaserep-19-812]--[@b29-amjcaserep-19-812],[@b31-amjcaserep-19-812],[@b32-amjcaserep-19-812],[@b34-amjcaserep-19-812]--[@b56-amjcaserep-19-812]\], we believe it is important to focus on the cases in which there were severe complications in order to form some conclusions and recommendations

The manufacturers recommend OC removal after hemostasis is obtained. If the surgeon decides to leave an OC gauze *in situ*, it should be used sparingly, as many problems have been attributed to excessive use \[[@b45-amjcaserep-19-812]\]. If OC is left *in situ*, the surgical report and the discharge document should state it in order to correctly inform the patient in detail about this condition.

In surgical procedures in rigid inextensible anatomical structures as the skull, spinal cord, and pleural cavity (in proximity to the spine), OC should be used with extreme care and, if possible, neurosurgical support should be used for better and safer hemostasis \[[@b32-amjcaserep-19-812]\] ([Table 3](#t3-amjcaserep-19-812){ref-type="table"}).

Moreover, when a mass is observed, accurate imaging evaluation and surgical history are required to assess a possible retained granulomatous lesion and to provide the best medical/surgical treatment.

Further studies are needed to determine if layer versus coiled disposal of oxidized cellulose may have a role in complications and to assess whether fibrillar oxidized cellulose is safer than the gauze form. Our surgical case report is fully compliant with the SCARE criteria \[[@b57-amjcaserep-19-812]\].

Conclusions
===========

Bleeding is a major intraoperative complication during surgical procedures. OC is an effective aid in hemostasis when ligature and diathermocoagulation are ineffective. Despite biocompatibility and reabsorption, cases of retained OC complications have been described in the literature. OC should be removed when hemostasis is obtained. If necessary, only a small quantity of OC should be placed *in situ* and it should be documented in the surgical report and the discharge document in order to correctly inform the patient. Accurate surgical history evaluation should always be performed, and multidisciplinary case evaluation between surgeons and radiologists should be done to achieve a more accurate diagnosis and prevent unnecessary revision surgery or further medical and/or surgical interventions. In case of surgical procedures with hemostatic control in rigid inextensible anatomical structures such as the skull and spinal cord, OC should be used with extreme care in order to avoid major complications and, if possible, neurosurgical support should be used for better and safer hemostasis. We also presented the first case of a complication following Gelita-Cel^®^ retention in a case of "neo-gallbladder". Our aim here is not to criticize the use of OC as hemostatic agent -- it has well-documented effectiveness in surgery -- but rather to provide some practical suggestions on how to avoid the severe complications reported in the literature.
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###### 

Imaging features of OC retention.

  ------------------------------------------------------------------------
  **Technique**   **Main characteristics**
  --------------- --------------------------------------------------------
  US              -- Complex mass\
                  -- Well-encapsulated hypoisoechoic lesion\
                  -- Circumscribed margins\
                  -- Internal hyperechoic nodules ("ile-flottante")\
                  -- Perilesional vascularization (Doppler)

  CT scan         -- Mixed-/low-attenuation mass\
                  -- Focal central collection of gas\
                  -- Absence of air-fluid levels\
                  -- Peripherical faint enhancement\
                  -- Proximity to the surgical site

  MRI             -- Nonspecific\
                  -- Hypointense stripes inside cystic-like cavity on T2

  PET/CT          -- Image with high glucose uptake\
                  -- False-positive
  ------------------------------------------------------------------------

###### 

Reported cases of OC retaining complications in the literature.

  **Author**                                         **Year**   **Age**   **Sex**   **Device**   **Surgical Site**   **Primary diagnosis**                    **Primary surgery**                                                                                         **Time (days)**   **Symptoms**                                       **Suspect**                 **Removal**
  -------------------------------------------------- ---------- --------- --------- ------------ ------------------- ---------------------------------------- ----------------------------------------------------------------------------------------------------------- ----------------- -------------------------------------------------- --------------------------- ----------------------------
  Dutton et al. \[[@b32-amjcaserep-19-812]\]         1983       35        M         Surgicel     Brain               Head injury                              Frontotemporal skull and lacerated left frontal lobe repair                                                 2,5 h             Vision impairment                                  Hematoma                    Yes
  Perez-Guerra et al. \[[@b31-amjcaserep-19-812]\]   1984       59        F         Surgicel     Thorax              Squamous cell carcinoma                  Left pneumonectomy                                                                                          2 h               Paraplegia                                         Cord compression            Yes
  Ito et al. \[[@b39-amjcaserep-19-812]\]            1989       n.a.      n.a.      OC           Brain               Intracranial meningioma                  Intracranial meningioma removal                                                                             390               Incidental                                         Large granuloma             Yes
  Ito et al. \[[@b39-amjcaserep-19-812]\]            1989       n.a.      n.a.      OC           Brain               Intracranial meningioma                  Intracranial meningioma removal                                                                             630               Incidental                                         Large granuloma             Yes
  Ito et al. \[[@b39-amjcaserep-19-812]\]            1989       n.a.      n.a.      OC           Brain               Anterior communicating artery aneurysm   Vascular treatment                                                                                          n.a.              Incidental                                         Large granuloma             Yes
  Short \[[@b28-amjcaserep-19-812]\]                 1990       72        F         OC           Thorax              Bronchogenic carcinoma                   Right upper/middle lobectomy                                                                                few days          Paraplegia                                         Cord compression            Yes
  Short \[[@b28-amjcaserep-19-812]\]                 1990       49        M         OC           Thorax              Lung adenocarcinoma                      Right upper lobectomy                                                                                       2                 Paraplegia                                         Cord compression            Yes
  Short \[[@b28-amjcaserep-19-812]\]                 1990       59        M         OC           Thorax              Bronchogenic carcinoma                   Right lower lobectomy                                                                                       3,5 h             Paraplegia                                         Cord compression            Yes
  Bradley et al. \[[@b40-amjcaserep-19-812]\]        1991       58        M         Oxycel       Abdomen             Cholecystitis                            Cholecystectomy                                                                                             120               Incidental                                         Abscess/Hematoma            No
  Deger et al. \[[@b41-amjcaserep-19-812]\]          1995       71        F         Surgicel     Abdomen             Ovary serous adenocarcinoma              Ovariectomy                                                                                                 150               Abdominal discomfort                               Tumor recurrence            Yes
  Sandhu et al. \[[@b42-amjcaserep-19-812]\]         1996       n.a.      n.a.      Surgicel     Brain               Intracranial meningioma                  Intracranial meningioma removal                                                                             60                Incidental                                         Tumor recurrence            Yes
  Sandhu et al. \[[@b42-amjcaserep-19-812]\]         1996       n.a.      n.a.      Surgicel     Brain               Intracranial meningioma                  Intracranial meningioma removal                                                                             360               Incidental                                         Tumor recurrence            Yes
  Iwabuchi et al. \[[@b43-amjcaserep-19-812]\]       1997       46        F         Surgicel     Thorax              n.a.                                     Right lower lobectomy                                                                                       1                 Paraplegia                                         n.a.                        Yes
  Concha et al. \[[@b37-amjcaserep-19-812]\]         1997       41        F         Surgicel     Abdomen             Kidney failure                           Kidney transplant                                                                                           570               Fever, abdominal pain, renal function impairment   Granuloma/neoplasia         Yes, allograft extirpation
  Banerjee et al. \[[@b44-amjcaserep-19-812]\]       1998       28        M         Surgicel     Spinal              Disk degeneration, spinal stenosis       Spinal decompression                                                                                        2                 Cauda equina syndrome                              Cord compression            Yes
  Lovstad et al. \[[@b29-amjcaserep-19-812]\]        1999       56        F         Surgicel     Thorax              Lung tumor                               Left lower lobectomy                                                                                        2,5 h             Paraplegia                                         Cord compression            Yes
  Azmy \[[@b35-amjcaserep-19-812]\]                  2001       2         M         Surgicel     Abdomen             Neuroblastoma                            Right adenectomy                                                                                            4                 Incidental                                         Tumor recurrence            Yes
  Ibrahim et al. \[[@b45-amjcaserep-19-812]\]        2002       53        F         Surgicel     Thorax              Aortic root aneurysm                     Aortic root replacement                                                                                     42                Incidental                                         Abscess                     Yes
  Gao et al. \[[@b46-amjcaserep-19-812]\]            2002       37        F         Surgicel     Pelvic              Hemoperitoneum, ruptured corpus luteum   Hysterectomy, right salpingo-oophorectomy                                                                   30                Abdominal pain, vaginal discharge                  Granuloma                   Yes
  Brodbelt et al. \[[@b27-amjcaserep-19-812]\]       2002       37        F         Surgicel     Thorax              Metastatic sarcoma                       Lung lobectomy                                                                                              1                 Paraplegia                                         Extradural mass             No
  Brodbelt et al. \[[@b27-amjcaserep-19-812]\]       2002       50        M         Surgicel     Thorax              Thoracic trauma                          Thoracic surgery                                                                                            3                 Weakness/numbness right leg                        Extradural mass             Yes
  Brodbelt et al. \[[@b27-amjcaserep-19-812]\]       2002       15 (m)    M         Surgicel     Thorax              n.a.                                     Cardiac surgery                                                                                             2                 Flaccid paraparesis, extradural mass               Extradural mass             Yes
  Farina Perez et al. \[[@b47-amjcaserep-19-812]\]   2004       63        F         Surgicel     Abdomen             Renal cell carcinoma                     Laparoscopic partial necrectomy                                                                             8                 Incidental                                         Gas collection              No
  Somani et al. \[[@b34-amjcaserep-19-812]\]         2005       62        F         Surgicel     Abdomen             Myelofibrosis                            Splenectomy                                                                                                 540               Renal tumor suspect                                Kidney tumor                Yes, necrectomy
  Arnold et al. \[[@b38-amjcaserep-19-812]\]         2007       55        M         Surgicel     Abdomen             n.a.                                     Cholecystectomy                                                                                             4                 Abdominal pain                                     Postoperative abscess       No
  Salmo et al. \[[@b48-amjcaserep-19-812]\]          2009       n.a.      M         Oxycel       Abdomen             Rectal cancer                            Colon resection                                                                                             90                Incidental                                         Tumor recurrence            Yes
  Agarwal et al. \[[@b49-amjcaserep-19-812]\]        2010       47        M         Surgicel     Abdomen             Renal cyst                               Laparoscopic nephron-sparing surgery                                                                        90                Incidental                                         Kidney mass                 No
  Royds et al. \[[@b36-amjcaserep-19-812]\]          2012       56        F         Surgicel     Cervical            Multinodular goiter                      Total thyroidectomy                                                                                         30                Wound swelling                                     Suture abscess              Yes
  Tefik et al. \[[@b50-amjcaserep-19-812]\]          2012       50        F         Surgicel     Abdomen             Cystic papillary renal cell carcinoma    Laparoscopic nephron-sparing surgery                                                                        180               Incidental                                         Heterogeneous mass          Yes
  Wang et al. \[[@b51-amjcaserep-19-812]\]           2013       83        M         Surgicel     Abdomen             GIST                                     Recurrent GIST                                                                                              120               GIST recurrence                                    Heterogeneous mass          Yes
  Behbehani et al. \[[@b52-amjcaserep-19-812]\]      2013       47        F         Surgicel     Pelvic              Uterine leiomyoma                        Laparoscopic total hysterectomy, bilateral salpingo-oophorectomy                                            21                Pelvic pain, fever                                 Postoperative abscess       No
  Behbehani et al. \[[@b52-amjcaserep-19-812]\]      2013       46        F         Surgicel     Pelvic              Uterine leiomyoma and adenomyosis        Laparoscopic total hysterectomy                                                                             10                Abdominal pain, fever                              Postoperative abscess       Yes
  Tam et al. \[[@b53-amjcaserep-19-812]\]            2014       50        F         Surgicel     Pelvic              Endometriosis                            Laparoscopic hysterectomy                                                                                   6                 Pelvic pain                                        Gas collection              No
  Tam et al. \[[@b53-amjcaserep-19-812]\]            2014       45        F         Surgicel     Pelvic              Endometriosis                            Robotic-assisted laparoscopic hysterectomy, left salpingo-oophorectomy, right salpingectomy, appendectomy   10                Abdominal pain, vaginal discharge                  Abscess                     No
  Tam et al. \[[@b53-amjcaserep-19-812]\]            2014       43        F         Surgicel     Pelvic              Endometriosis                            Laparoscopic hysterectomy, left oophorectomy, bilateral salpingectomy                                       4                 Malaise                                            Abscess                     No
  Zhang et al. \[[@b54-amjcaserep-19-812]\]          2015       21        F         Surgicel     Pelvic              Symptomatic ovarian cyst                 Ovarian cystectomy                                                                                          7                 Pelvic pain                                        Heterogeneous mass          No
  Cormio et al. \[[@b55-amjcaserep-19-812]\]         2016       67        F         Surgicel     Pelvic              Cystocele, anterior genital prolapse     Pubovaginal sling, cystocele repair                                                                         180               Irritative voiding symptoms                        Ovarian cancer              Yes
  Singh et al. \[[@b56-amjcaserep-19-812]\]          2016       71        M         Surgiflo     Abdomen             Clear cell carcinoma                     Left robotic partial nephrectomy                                                                            30                Nodular lesion                                     Recurrence/residual tumor   No

###### 

Practical suggestions for safe use of OC.

  -----------------------------------------------------------------------------------------------
  Practical suggestion
  -- Remove OC after hemostasis
  -- If left *in situ*, use it sparingly
  -- Report the use of OC in the surgical report
  -- Inform the patient about OC retention
  -- Use extreme care in rigid non-extensive anatomical structures (eventual neurosurgical aid)
  -- Accurate surgical history evaluation
  -----------------------------------------------------------------------------------------------

[^1]: Authors' Contribution:

[^2]: Study Design

[^3]: Data Collection

[^4]: Statistical Analysis

[^5]: Data Interpretation

[^6]: Manuscript Preparation

[^7]: Literature Search

[^8]: Funds Collection

[^9]: **Conflict of interest:** None declared
